Foley Hoag LLP represented Ginkgo Bioworks on the agreement. Ginkgo Bioworks (NYSE: DNA) announced a collaboration with Pfizer (NYSE: PFE) focused on the discovery of RNA-based drug...
You must be a Standard 1 Year member to access this content.
Foley Hoag represented Ginkgo Bioworks on the deal. Ginkgo Bioworks (NYSE: DNA) (“Ginkgo”), the leading platform for cell programming and biosecurity, announced its acquisition of StrideBio’s adeno-associated...
You must be a Standard 1 Year member to access this content.
Foley Hoag LLP represented Alcyone Therapeutics on the deal. Alcyone Therapeutics (Alcyone) announced the negotiation of a license and collaboration agreement with Biogen Inc. (Nasdaq: BIIB) to...
You must be a Standard 1 Year member to access this content.
Foley Hoag LLP represented Ginkgo Bioworks on the deal. Ginkgo Bioworks, Inc. (NYSE: DNA), the leading horizontal platform for cell programming, closed a collaboration agreement with...
You must be a Standard 1 Year member to access this content.
Foley Hoag LLP represented Ginkgo Bioworks, Inc. on the deal. Ginkgo Bioworks, Inc. (NYSE: DNA), the leading horizontal platform for cell programming, closed a collaboration agreement with...
You must be a Standard 1 Year member to access this content.
IN BRIEF: Bird & Bird, Foley Hoag LLP, Goodwin Procter, advised on the matter. Bird & Bird advised SparingVision SAS with a team including Emmanuelle Porte...
You must be a Standard 1 Year member to access this content.
Foley Hoag LLP advised Ginkgo Bioworks on the deal. Ginkgo Bioworks, Inc., the organism company, closed a collaboration and license agreement with Biogen (Nasdaq: BIIB) to...
You must be a Standard 1 Year member to access this content.
Foley Hoag LLP advised Ginkgo Bioworks on the deal. Ginkgo Bioworks, Inc., the organism company, closed a collaboration and license agreement with Biogen (Nasdaq: BIIB) to...
You must be a Standard 1 Year member to access this content.
